InvestorsHub Logo
Followers 134
Posts 7040
Boards Moderated 0
Alias Born 02/09/2012

Re: bradfordbros post# 383947

Friday, 11/12/2021 10:01:02 AM

Friday, November 12, 2021 10:01:02 AM

Post# of 402718
Bradford...

Undoubtedly " he is equally disappointed but how can it be his fault the top-line data wasn’t met "

Amazing ignorance and theatrics over of "off with his head" because top-line was not met. If it failure of the top line in a clinical trial was deemed a "criminal" responsibility of the pharma CEO...there would be no Pharma Industry.

Bounty Hunters looking for Leo's head, and allegedly "screwed the pooch"...over the following statement in yesterday's PR:

"In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug."

It understandably led to multiple misunderstandings.



When anyone reading the public information on the Trials Placebo/Brilacidin breakdown (both official CT sites and PR of the company) would KNOW...of the 120 patients included 60 received Brilacidin and 60 received SOC.

Hardly actionable...

Perhaps it could have been stated more clearly as...for those who know better, but wish to create an issue, where there is none.

"In the trial, 120 patients were treated, (and as CLEARLY STATED in the CT protocol, 60 receiving Placebo (SOC) and 60 receiving Brilacidin), with three-fourths of the Brilacidin administered patients receiving 5 days of study drug."

down 50%, but IMO Brilacidin still has too much opportunity in its pipeline to sell, especially with the pedigree behind Brilacidin in support of it's potential. I look forward to OM moving forward beginning Jan and 1st Quarter...



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News